Thalidomide Plus Dexamethasone As A Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation Improves Progression-free Survival In Multiple Myeloma

dc.creatorMaiolino A.
dc.creatorHungria V.T.
dc.creatorGarnica M.
dc.creatorOliveira-Duarte G.
dc.creatorOliveira L.C.
dc.creatorMercante D.R.
dc.creatorMiranda E.C.
dc.creatorQuero A.A.
dc.creatorPeres A.L.
dc.creatorBarros J.C.
dc.creatorTanaka P.
dc.creatorMagalhaes R.P.
dc.creatorRego E.M.
dc.creatorLorand-Metze I.
dc.creatorLima C.S.
dc.creatorRenault I.Z.
dc.creatorBraggio E.
dc.creatorChiattone C.
dc.creatorNucci M.
dc.creatorde Souza C.A.
dc.date2012
dc.date2015-06-26T20:29:41Z
dc.date2015-11-26T14:26:14Z
dc.date2015-06-26T20:29:41Z
dc.date2015-11-26T14:26:14Z
dc.date.accessioned2018-03-28T21:29:13Z
dc.date.available2018-03-28T21:29:13Z
dc.identifier
dc.identifierAmerican Journal Of Hematology. , v. 87, n. 10, p. 948 - 952, 2012.
dc.identifier3618609
dc.identifier10.1002/ajh.23274
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84866770848&partnerID=40&md5=78c92484326b361da359dfe0b7447796
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/97124
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/97124
dc.identifier2-s2.0-84866770848
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1246025
dc.descriptionDespite the good response of stem cell transplant (SCT) in the treatment of multiple myeloma (MM), most patients relapse or do not achieve complete remission, suggesting that additional treatment is needed. We assessed the impact of thalidomide in maintenance after SCT in untreated patients with MM. A hundred and eight patients (<70 years old) were randomized to receive maintenance with dexamethasone (arm A; n = 52) or dexamethasone with thalidomide (arm B; n = 56; 200 mg daily) for 12 months or until disease progression. After a median follow-up of 27 months, an intention to treat analysis showed a 2-year progression-free survival (PFS) of 30% in arm A (95% CI 22-38) and 64% in arm B (95% CI 57-71; P = 0.002), with median PFS of 19 months and 36 months, respectively. In patients who did not achieve at least a very good partial response, the PFS at 2 years was significantly higher when in use of thalidomide (19 vs. 59%; P = 0.002). Overall survival at 2 years was not significantly improved (70 vs. 85% in arm A and arm B, respectively; P = 0.27). The addition of thalidomide to dexamethasone as maintenance improved the PFS mainly in patients who did not respond to treatment after SCT. © 2012 Wiley Periodicals, Inc.
dc.description87
dc.description10
dc.description948
dc.description952
dc.descriptionAttal, M., Harousseau, J.L., Stoppa, A.M., A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome (1996) N Engl J Med, 335, pp. 91-97
dc.descriptionChild, J.A., Morgan, G.J., Davies, F.E., High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma (2003) N Engl J Med, 348, pp. 1875-1883
dc.descriptionAttal, M., Harousseau, J.L., Leyvraz, S., Maintenance therapy with thalidomide improves survival in patients with multiple myeloma (2006) Blood, 108, pp. 3289-3294
dc.descriptionSpencer, A., Prince, H.M., Roberts, A.W., Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure (2009) J Clin Oncol, 27, pp. 1788-1793
dc.descriptionBarlogie, B., Desikan, R., Eddlemon, P., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients (2001) Blood, 98, pp. 492-494
dc.descriptionCriteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group (2003) Br J Haematol, 121, pp. 749-757
dc.descriptionBlade, J., Samson, D., Reece, D., Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant (1998) Br J Haematol, 102, pp. 1115-1123
dc.descriptionAttal, M., Harousseau, J.L., Facon, T., Single versus double autologous stem-cell transplantation for multiple myeloma (2003) N Engl J Med, 349, pp. 2495-2502
dc.descriptionSpencer, A., Seldon, M., Deveridge, S., Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients (2004) Hematol J, 5, pp. 216-221
dc.descriptionBarlogie, B., Tricot, G., Anaissie, E., Thalidomide and hematopoietic-cell transplantation for multiple myeloma (2006) N Engl J Med, 354, pp. 1021-1030
dc.descriptionLokhorst, H.M., van der Holt, B., Zweegman, S., A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma (2010) Blood, 115, pp. 1113-1120
dc.descriptionMorgan, G.J., Davies, F.E., Gregory, W.M., The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis (2012) Blood, 119, pp. 7-15
dc.descriptionStewart, A.K., Trudel, S., Bahlis, N.J., A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): The NCIC CTG MY.10 Trial (2010) ASH Annu Meeting Abstr, 116, p. 39
dc.descriptionSinghal, S., Mehta, J., Desikan, R., Antitumor activity of thalidomide in refractory multiple myeloma (1999) N Engl J Med, 341, pp. 1565-1571
dc.descriptionRajkumar, S.V., Hayman, S., Gertz, M.A., Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma (2002) J Clin Oncol, 20, pp. 4319-4323
dc.descriptionBarlogie, B., Attal, M., Crowley, J., Long-term follow-up of autotransplantation trials for multiple myeloma: Update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences (2010) J Clin Oncol, 28, pp. 1209-1214
dc.descriptionLudwig, H., Adam, Z., Tóthová, E., Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma (2010) Haematologica, 95, pp. 1548-1554
dc.descriptionRichardson, P., Jagannath, S., Hussein, M., Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma (2009) Blood, 114, pp. 772-778
dc.descriptionAttal, M., Lauwers-Cances, V., Marit, G., Lenalidomide maintenance after stem-cell transplantation for multiple myeloma (2012), 366, pp. 1782-1791. , N Engl J MedMcCarthy, P.L., Owzar, K., Hofmeister, C.C., Hurd, D.D., Lenalidomide after stem-cell transplantation for multiple myeloma (2012) N Engl J Med, 366, pp. 1770-1781
dc.descriptionHungria, V.T., Maiolino, A., Martinez, G., Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma (2008) Haematologica, 93, pp. 791-792
dc.languageen
dc.publisher
dc.relationAmerican Journal of Hematology
dc.rightsfechado
dc.sourceScopus
dc.titleThalidomide Plus Dexamethasone As A Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation Improves Progression-free Survival In Multiple Myeloma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución